March 2016, Vol 9, Seventh Annual Payers' Guide

Chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (NHL) are common hematologic malignancies that represent a significant burden to patients and to the healthcare system. In light of the morbidity, mortality, and quality-of-life challenges associated with CLL and NHL, there is a marked need for additional therapeutic options for patients with these malignancies.
Lung cancer is the second most common cancer in the United States. In 2015, an estimated 221,200 new cases of lung cancer were diagnosed, representing 13.3% of all new cancer cases.
Diabetes is a chronic disease that affects a staggering 29.1 million in­dividuals in the United States—approximately 9.3% of the population.
There is an urgent unmet need for more effective therapies in pancreatic cancer. The American Cancer Society estimated that approximately 49,000 new cases of pancreatic cancer will be diagnosed in the United States in 2015, and more than 40,500 people will die from this cancer.
Lung cancer is the leading cause of cancer-related mortality in the United States among men and women. The most common type of the disease, non–small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases.
The National Cancer Institute estimated that in 2015 there were 73,870 new cases of skin melanoma and more than 9900 patients died from this disease.
Rosacea, a chronic, noncontagious dermatitis of the facial skin, affects approximately 16 million people in the United States.
Breast cancer is one of the most common cancer diagnoses in the United States. The National Cancer Institute estimates that 231,840 American women will be diagnosed with breast cancer, and nearly 40,300 women will die from the disease in 2015.
American Health & Drug Benefits publishes a Payers' Guide to New FDA Approvals annually with the goal of providing payers and other healthcare stakeholders a comprehensive review of pharmaceuticals that were newly approved or that received important new indications by the US Food and Drug Administration (FDA) in the previous year.
The year 2015 was interesting for new drug approvals. As was the case in the recent past, these approvals were dominated by specialty drugs, many of which were first-in-class therapies.
Page 2 of 5
Results 11 - 20 of 43
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • National Association of Specialty Pharmacy
  • Lynx CME